1. Kim, Hyungsoo, Kim, Heejung, Feng, Yongmei, Tocci, Stefania, Ronai, Ze'ev A. . PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. In Science translational medicine, 12, . doi:10.1126/scitranslmed.aaz5683. https://pubmed.ncbi.nlm.nih.gov/32641491/
2. Downs, Isaac, Vijayan, Saptha, Sidiq, Tabasum, Kobayashi, Koichi S. 2016. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression. In BioFactors (Oxford, England), 42, 349-57. doi:10.1002/biof.1285. https://pubmed.ncbi.nlm.nih.gov/27087581/
3. Chou, Wei-Chun, Jha, Sushmita, Linhoff, Michael W, Ting, Jenny P-Y. 2023. The NLR gene family: from discovery to present day. In Nature reviews. Immunology, 23, 635-654. doi:10.1038/s41577-023-00849-x. https://pubmed.ncbi.nlm.nih.gov/36973360/
4. Sun, Xin, Watanabe, Toshiyuki, Oda, Yoshitaka, Tanaka, Shinya, Kobayashi, Koichi S. 2024. Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I. In Proceedings of the National Academy of Sciences of the United States of America, 121, e2310821121. doi:10.1073/pnas.2310821121. https://pubmed.ncbi.nlm.nih.gov/38300873/
5. Yoshihama, Sayuri, Vijayan, Saptha, Sidiq, Tabasum, Kobayashi, Koichi S. 2017. NLRC5/CITA: A Key Player in Cancer Immune Surveillance. In Trends in cancer, 3, 28-38. doi:10.1016/j.trecan.2016.12.003. https://pubmed.ncbi.nlm.nih.gov/28718425/
6. Liu, Zhaolin, Shen, Chenye, Li, Heng, Fei, Jian, Huang, Fang. 2023. NOD-like receptor NLRC5 promotes neuroinflammation and inhibits neuronal survival in Parkinson's disease models. In Journal of neuroinflammation, 20, 96. doi:10.1186/s12974-023-02755-4. https://pubmed.ncbi.nlm.nih.gov/37072793/
智鼠故事 
